Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||central nervous system cancer||not applicable||CC-122||Phase I||Actionable||In a Phase I trial, Avadomide (CC-122) treatment was well tolerated in patients with central nervous system tumors, and resulted in a 6-month progression-free survival (PFS) rate of 83% (5/6) and a PFS ranging from 58 to 1,079 days (PMID: 30201761; NCT01421524).||30201761|
|Unknown unknown||central nervous system cancer||not applicable||CC-122||Phase I||Actionable||In a Phase I trial, CC-122 demonstrated safety and preliminary efficacy in patients with glioblastom and other central nervous system tumors, resulted in a meidan progressin-free survival of 58 days (Neuro Oncol (2016) 18 (suppl 6): vi24.).||detail...|
|PubMed Id||Reference Title||Details|
|A PHASE 1A/1B, MULTI-CENTER, OPEN-LABEL DOSE FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF THE PLEIOTROPIC PATHWAY MODIFIER CC-122 ADMINISTERED ORALLY TO PATIENTS WITH GLIOBLASTOMA MULTIFORME (GBM) AND OTHER BRAIN TUMORS||Full reference...|
|(30201761)||A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies.||Full reference...|